"Among all the weight loss drugs, Ozempic has become a phenomenon. With as much as $17 billion in sales in 2024 and over $14 billion in the first nine months of 2025, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S ( NYSE: NVO). This Scandinavian economic behemoth was one of the highest-valued companies in Europe at over $500 billion, which exceeds Denmark's entire gross domestic product."
"Ironically, Ozempic and Wegovy, like many of Novo Nordisk's other products, were created primarily for treating diabetes. The weight-loss factor has become a very profitable and unintended side effect. Founded a century ago, Copenhagen-based Nordisk originally made insulin. After coming to the United States in 1982, it underwent several corporate changes until becoming Novo Nordisk in 1989. In addition to diabetes drugs, the company also makes drug treatments for wound healing, menopausal hormone replacement, and human growth hormone."
Novo Nordisk generated roughly $17 billion in 2024 and over $14 billion in the first nine months of 2025 from GLP-1 drugs, pushing its value above $500 billion. Ozempic and Wegovy were developed for diabetes, with weight loss emerging as a lucrative, unintended effect. The company began as Nordisk a century ago, entered the U.S. in 1982, and became Novo Nordisk in 1989, producing diabetes therapies and treatments for wound healing, menopausal hormone replacement, and growth hormone. The pipeline includes amycretin (phase 1), CagriSema (phase 2), a promising weight-loss pill, corporate restructuring, and forecasts of a $100 billion obesity market by 2030, prompting investor focus on long-term prospects.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]